ArticleSurgical endoscopy2026
Long-term outcome of peroral endoscopic myotomy for sigmoid-type achalasia: S1 vs S2 subtypes.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Symptom duration is associated with esophageal remodeling in achalasia treated by peroral endoscopic myotomy.Scientific reports · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND AND
aimsThe sigmoid-type achalasia is an advanced stage of achalasia characterized by severe dilatation, tortuous angulation, and rotation of the esophageal body. Our aim is to explore the safety, and efficacy of peroral endoscopic myotomy (POEM) for sigmoid-type achalasia. MATERIALS AND
methodsA total of 78 patients who underwent POEM for sigmoid-type achalasia were retrospectively included. The primary outcome was clinical success, defined as a postoperative Eckardt score ≤ 3 points. Secondary outcomes were perioperative adverse events (AEs), and procedure-related parameters.
resultsThe mean pre-POEM Eckardt score was 7.3 ± 2.0 and 52 patients (66.7%) had a disease duration of ≥ 10 years. S1 type was found in 62 patients and S2 type in 16 patients. The technical success rate was 100%. The mean procedure duration was 80.4 ± 40.5 min and the mean hospital stay was 2.9 ± 1.7 days. Intraoperative mucosal injury occurred in 18 (23.1%) patients, including 14 (17.9%) type I and 4 (5.1%) type II. All mucosal injury were clipped and did not induce any complications. CT revealed gas-related AEs in 7 cases (9.0%), pleural effusions in 10 cases (12.8%), pneumonitis in 10 cases (12.8%), and focal atelectasis in 6 cases (7.7%). The above AEs only appear on CT scans, are asymptomatic, and do not require intervention. Major AEs were found in 1 patient. This patient developed a postoperative pleural effusion that required drainage. The clinical failure rate at 2-year, 5-year, and 10-year follow-up visits were 1.3%, 12.8%, and 42.5%, respectively. There were no significant differences between type S1 and S2 achalasia in terms of procedure-related parameters, AEs and clinical failure rates.
conclusionsPOEM is a safe and effective procedure for sigmoid-type achalasia at the 2-year and 5-year follow-up visits. However, a significant rate of clinical failure was observed at 10 years, highlighting that long-term durability remains a concern in managing this advanced disease stage. Clinical outcomes were similar for both S1 and S2 types of achalasia.
Indexed as
Identifiers
41201588What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.